PortfoliosLab logoPortfoliosLab logo
ALNY vs. VKTX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ALNY vs. VKTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Alnylam Pharmaceuticals, Inc. (ALNY) and Viking Therapeutics, Inc. (VKTX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ALNY achieves a -26.53% return, which is significantly lower than VKTX's -16.88% return. Over the past 10 years, ALNY has underperformed VKTX with an annualized return of 16.55%, while VKTX has yielded a comparatively higher 36.31% annualized return.


ALNY

1D
-3.59%
1M
-0.98%
YTD
-26.53%
6M
-32.06%
1Y
-2.88%
3Y*
15.25%
5Y*
13.17%
10Y*
16.55%

VKTX

1D
2.78%
1M
-6.67%
YTD
-16.88%
6M
-23.01%
1Y
5.07%
3Y*
6.41%
5Y*
39.22%
10Y*
36.31%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ALNY vs. VKTX - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ALNY
Alnylam Pharmaceuticals, Inc.
-26.53%68.99%22.94%-19.46%40.14%30.48%12.85%57.96%-42.61%239.34%
VKTX
Viking Therapeutics, Inc.
-16.88%-12.57%116.23%97.98%104.35%-18.29%-29.80%4.84%88.42%241.18%

Correlation

The correlation between ALNY and VKTX is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.19

Correlation (3Y)
Calculated over the trailing 3-year period

0.25

Correlation (5Y)
Calculated over the trailing 5-year period

0.30

Correlation (10Y)
Calculated over the trailing 10-year period

0.32

Correlation (All Time)
Calculated using the full available price history since Apr 29, 2015

0.28

The correlation between ALNY and VKTX shifts across timeframes, from 0.19 (1 year) to 0.32 (10 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

ALNY:

$40.38B

VKTX:

$3.38B

EPS

ALNY:

$4.26

VKTX:

-$4.16

PB Ratio

ALNY:

37.55

VKTX:

6.73

Total Revenue (TTM)

ALNY:

$4.29B

VKTX:

$0.00

Gross Profit (TTM)

ALNY:

$2.51B

VKTX:

-$208.00K

EBITDA (TTM)

ALNY:

$729.86M

VKTX:

-$501.77M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ALNY vs. VKTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ALNY
ALNY Risk / Return Rank: 3838
Overall Rank
ALNY Sharpe Ratio Rank: 3939
Sharpe Ratio Rank
ALNY Sortino Ratio Rank: 3535
Sortino Ratio Rank
ALNY Omega Ratio Rank: 3434
Omega Ratio Rank
ALNY Calmar Ratio Rank: 4040
Calmar Ratio Rank
ALNY Martin Ratio Rank: 4040
Martin Ratio Rank

VKTX
VKTX Risk / Return Rank: 4646
Overall Rank
VKTX Sharpe Ratio Rank: 4444
Sharpe Ratio Rank
VKTX Sortino Ratio Rank: 4747
Sortino Ratio Rank
VKTX Omega Ratio Rank: 4949
Omega Ratio Rank
VKTX Calmar Ratio Rank: 4545
Calmar Ratio Rank
VKTX Martin Ratio Rank: 4545
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ALNY vs. VKTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Alnylam Pharmaceuticals, Inc. (ALNY) and Viking Therapeutics, Inc. (VKTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ALNYVKTXDifference
Sharpe ratioReturn per unit of total volatility

-0.15

Sortino ratioReturn per unit of downside risk

-0.48

Omega ratioGain probability vs. loss probability

1.02

1.10

-0.08

Calmar ratioReturn relative to maximum drawdown

-0.07

0.11

-0.18

Martin ratioReturn relative to average drawdown

-0.12

0.23

-0.35

ALNY vs. VKTX - Sharpe Ratio Comparison

The current ALNY Sharpe Ratio is -0.08, which is lower than the VKTX Sharpe Ratio of 0.07. The chart below compares the historical Sharpe Ratios of ALNY and VKTX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


ALNYVKTXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.08

0.07

-0.15

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.27

0.39

-0.12

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.31

0.38

-0.07

Sharpe Ratio (All Time)

Calculated using the full available price history

0.32

0.11

+0.21

Drawdowns

ALNY vs. VKTX - Drawdown Comparison

The maximum ALNY drawdown since its inception was -83.58%, smaller than the maximum VKTX drawdown of -90.41%. Use the drawdown chart below to compare losses from any high point for ALNY and VKTX.


Loading charts...

Drawdown Indicators


ALNYVKTXDifference

Max Drawdown

Largest peak-to-trough decline

-83.58%

-90.41%

+6.83%

Max Drawdown (1Y)

Largest decline over 1 year

-42.01%

-45.14%

+3.13%

Max Drawdown (3Y)

Largest decline over 3 years

-42.01%

-78.86%

+36.85%

Max Drawdown (5Y)

Largest decline over 5 years

-42.46%

-78.86%

+36.40%

Max Drawdown (10Y)

Largest decline over 10 years

-59.95%

-89.26%

+29.31%

Current Drawdown

Current decline from peak

-40.52%

-69.06%

+28.54%

Average Drawdown

Average peak-to-trough decline

-30.59%

-60.02%

+29.43%

Ulcer Index

Depth and duration of drawdowns from previous peaks

23.22%

22.54%

+0.68%

Volatility

ALNY vs. VKTX - Volatility Comparison

The current volatility for Alnylam Pharmaceuticals, Inc. (ALNY) is 9.94%, while Viking Therapeutics, Inc. (VKTX) has a volatility of 14.20%. This indicates that ALNY experiences smaller price fluctuations and is considered to be less risky than VKTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ALNYVKTXDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.94%

14.20%

-4.26%

Volatility (6M)

Calculated over the trailing 6-month period

26.34%

40.45%

-14.11%

Volatility (1Y)

Calculated over the trailing 1-year period

36.87%

74.12%

-37.25%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

48.88%

101.63%

-52.75%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

53.66%

97.07%

-43.41%

Dividends

ALNY vs. VKTX - Dividend Comparison

Neither ALNY nor VKTX has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ALNY vs. VKTX - Financials Comparison

This section allows you to compare key financial metrics between Alnylam Pharmaceuticals, Inc. and Viking Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M1.00B1.20B20222023202420252026
1.17B
0
(ALNY) Total Revenue
(VKTX) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ALNY and VKTX have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

VKTX has higher volatility (14.20%) compared to ALNY (9.94%). In terms of maximum drawdown, ALNY dropped -83.58% vs VKTX's -90.41%.

VKTX currently has the higher Sharpe Ratio (0.07 vs -0.08), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ALNY and VKTX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer